Kurt Schroeder

587 total citations
18 papers, 342 citations indexed

About

Kurt Schroeder is a scholar working on Genetics, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Kurt Schroeder has authored 18 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 6 papers in Public Health, Environmental and Occupational Health and 6 papers in Hematology. Recurrent topics in Kurt Schroeder's work include Childhood Cancer Survivors' Quality of Life (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Kurt Schroeder is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Kurt Schroeder collaborates with scholars based in United States, Germany and Ireland. Kurt Schroeder's co-authors include Rayna Venook, Man Ping Wang, Kathy Hötzel, Brad Bolon, Luc Desnoyers, Luis A. Rodríguez, Maria Hristopoulos, Dorothy French, Ronald E. Ferrando and Avi Ashkenazi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Kurt Schroeder

16 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kurt Schroeder United States	6	170	88	60	59	56	18	342
Ci Pan China	14	70 0.4×	157 1.8×	109 1.8×	107 1.8×	29 0.5×	37	405
April Sorrell United States	9	114 0.7×	201 2.3×	71 1.2×	90 1.5×	105 1.9×	18	498
Wenyuan Mai China	13	199 1.2×	66 0.8×	10 0.2×	81 1.4×	50 0.9×	44	442
R. Mauritz Netherlands	9	124 0.7×	92 1.0×	30 0.5×	130 2.2×	23 0.4×	14	427
Edward Kwan Australia	10	57 0.3×	213 2.4×	79 1.3×	87 1.5×	31 0.6×	20	337
Elva Jiménez‐Hernández Mexico	10	95 0.6×	105 1.2×	68 1.1×	95 1.6×	27 0.5×	33	312
Guillaume Richard‐Carpentier United States	12	118 0.7×	179 2.0×	42 0.7×	101 1.7×	68 1.2×	27	370
Min‐Yuan Wu China	11	173 1.0×	267 3.0×	148 2.5×	65 1.1×	20 0.4×	41	434
Luciana Correa Oliveira de Oliveira Brazil	10	138 0.8×	38 0.4×	14 0.2×	88 1.5×	60 1.1×	31	330
Bachar Samra United States	9	97 0.6×	113 1.3×	23 0.4×	136 2.3×	38 0.7×	18	364

Countries citing papers authored by Kurt Schroeder

Since Specialization

Citations

This map shows the geographic impact of Kurt Schroeder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt Schroeder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt Schroeder more than expected).

Fields of papers citing papers by Kurt Schroeder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt Schroeder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt Schroeder. The network helps show where Kurt Schroeder may publish in the future.

Co-authorship network of co-authors of Kurt Schroeder

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt Schroeder. A scholar is included among the top collaborators of Kurt Schroeder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt Schroeder. Kurt Schroeder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Gotlib, Jason, John H. Baird, Tracy I. George, et al.. (2019). A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Advances. 3(15). 2264–2271. 12 indexed citations

Bose, Prithviraj, Mahesh Swaminathan, Naveen Pemmaraju, et al.. (2019). A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leukemia & lymphoma. 60(7). 1767–1774. 24 indexed citations

Bose, Prithviraj, Naveen Pemmaraju, Kurt Schroeder, et al.. (2017). Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF). Blood. 130. 1632–1632. 2 indexed citations

Baird, John H., Srđan Verstovšek, Tracy I. George, et al.. (2017). Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis. Blood. 130. 2909–2909. 1 indexed citations

Badruddoja, Michael, Abhay Sanan, Kurt Schroeder, et al.. (2017). Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Cancer Chemotherapy and Pharmacology. 80(4). 715–721. 23 indexed citations

Schroeder, Kurt, et al.. (2015). Vancomycin use in a rural hospital: a 3-year retrospective study.. PubMed. 20(2). 56–62. 3 indexed citations

Rytting, Michael, Deborah A. Thomas, Susan O’Brien, et al.. (2014). Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 120(23). 3660–3668. 75 indexed citations

Rytting, Michael, Deborah A. Thomas, Susan O’Brien, et al.. (2013). Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL). Blood. 122(21). 1400–1400. 2 indexed citations

French, Dorothy, Benjamin C. Lin, Man Ping Wang, et al.. (2012). Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models. PLoS ONE. 7(5). e36713–e36713. 167 indexed citations

10.

Shastri, Aditi, Jörge E. Cortes, Elias Jabbour, et al.. (2012). A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia. Blood. 120(21). 1728–1728. 3 indexed citations

11.

Curtis, Donald A., et al.. (2012). Identifying Student Misconceptions in Biomedical Course Assessments in Dental Education. Journal of Dental Education. 76(9). 1183–1194. 13 indexed citations

12.

Shastri, Aditi, Tapan M. Kadia, Jörge E. Cortes, et al.. (2011). Phase II Study of Low-Dose Pomalidomide in Patients with Myelofibrosis and Significant Anemia (hemoglobin <10g/dL). Blood. 118(21). 1757–1757.

13.

Rytting, Michael, Deborah A. Thomas, Elias Jabbour, et al.. (2011). Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Modified Augmented Berlin-Frankfurt-Muenster (ABFM) Therapy. Blood. 118(21). 1527–1527. 1 indexed citations

14.

Rytting, Michael, Hagop M. Kantarjian, Deborah A. Thomas, et al.. (2010). Adolescent and Young Adult Patients Treated with Modified Augmented Berlin-Frankfurt-Muenster Therapy. Blood. 116(21). 3250–3250. 3 indexed citations

15.

Badruddoja, Michael, Baldassarre Stea, M.C. Bishop, et al.. (2010). Phase II study of biweekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma multiforme.. Journal of Clinical Oncology. 28(15_suppl). e12554–e12554. 3 indexed citations

16.

Schroeder, Kurt, et al.. (2009). 5-Jahres-Ergebnisse der zementfreien Allofit®-Press-fit-Pfanne. Der Orthopäde. 39(1). 87–91. 5 indexed citations

17.

Ayala, George, et al.. (2007). Acción Mutua (Shared Action). Journal of Public Health Management and Practice. 13(Supplement). S33–S39. 4 indexed citations

18.

Schroeder, Kurt, et al.. (2000). Einsatz von Identifikationsmethoden zur Integration von Simulation und Versuch bei fahrdynamischen Untersuchungen. elib (German Aerospace Center). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact